Hormone replacement therapy and the cardiovascular system lessons learned and unanswered questions.
Cardiovascular disease is the leading cause of death among women in the U.S., exceeding breast cancer mortality in women of all ages. Women present with cardiovascular disease a decade after men, and this has been attributed to the protective effect of female ovarian sex hormones that is lost after menopause. Animal and observational studies have shown beneficial effects of hormone therapy when it is initiated early in the perimenopausal period or before the development of significant atherosclerosis. However, randomized, placebo-controlled trials in older women have not shown any benefit in either primary prevention or secondary prevention of cardiovascular events, with a concerning trend toward harm. This review outlines the lessons learned from the basic science, animal, observational, and randomized trials, and then summarizes yet-unanswered questions of hormone therapy and cardiovascular risk.
Ouyang
Pamela
P
Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. pouyang@jhmi.edu
Michos
Erin D
ED
Karas
Richard H
RH